Effects of Anesthetic Methods on Hepatic Cancer Cell Function in Vitro
NCT ID: NCT04510935
Last Updated: 2021-01-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
35 participants
INTERVENTIONAL
2020-08-20
2020-12-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Anesthetic Methods on Hepatic Cancer Cell Malignancy
NCT03594188
Laparoscope Anatomical and Aon-anatomical Hepatectomy
NCT02009176
Hepatocellular Carcinoma Recurrence and Anesthesia
NCT02643173
Laparoscopic Surgery Versus Radiofrequency Ablation for Recurrent HCC
NCT02535117
Radiofrequency-assisted Hepatectomy on the Outcomes of HCC Patients With Cirrhosis
NCT01992978
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients from GA group will receive anesthesia induced with 0.05-0.1mg/kg intravenous midazolam, 3-6ug/kg fentanyl, 1.0-2.5mg/kg propofol and 0.1-0.2mg/kg atracurium. Laryngeal mask will be used to maintain ventilation. Anesthesia will be maintained with 4-8mg/kg/h propofol and 0.1-0.3ug/kg/min remifentanil, and additional non-depolarizing muscle relaxant when necessary. In patients from LA group, analgesia will be provided by a subcutaneous injection of 2% lidocaine by the surgeons before insertion of the needles.
Serum will be collected from patients of both groups at before induction and 1h post-surgery. The HepG2 hepatic cancer cell line will be treated with patient serum from both groups. The effects of anesthetic methods on cellular invasion, migration, proliferation will be measured. The expression levels of inflammatory cytokines in the serum from patients of both groups will also be analyzed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
general anesthesia
Patients in this group will have RF ablation for treatment of HCC under general anesthesia.
general anesthesia
the patient will receive general anesthesia during surgery in this group.
local anesthesia
In this group, patients will receive radiofrequency ablation under local anesthesia.
local anesthesia
the patient will receive local anesthesia during surgery in this group.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
general anesthesia
the patient will receive general anesthesia during surgery in this group.
local anesthesia
the patient will receive local anesthesia during surgery in this group.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ASA grade I-III
* Diagnosed with a single primary liver tumor of 3cm or smaller
* Is scheduled for elective radiofrequency ablation surgery
* With no macro-vascular invasion, no lymph node or extrahepatic metastases
* Child-Pugh Class A or B
Exclusion Criteria
* severe systemic disease (heart, lung, kidney, or immune system)
* INR\>1.5 or platelet count \<45,000 cells/mm3
* a history of addiction to opioids;
* Disagree to participate the trial
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
RenJi Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jie Tian
Principle Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jie Tian
Role: PRINCIPAL_INVESTIGATOR
RenJi Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Renji Hospital affliated to Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HCCRA202008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.